1. Anderson M, Storm H and Mouridsen HT (1991): Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early cancer. J Natl Cancer Inst 83:1013–1017
2. Anzai Y, Holinka CF, Hirouki K Na Gurpide E (1989): Stimulatory effects of 4-hydroxytamoxifen on proliferation of human endometrial adenocarcinoma cells (Ishikawa line). Cancer Res 49:2362–2365
3. Arai Y, Mori T, Suzuki Y and Bern HA (1983): Long-term effects of perinatal exposure to sex steroids and diethystilbestrol on the reproductive system of male mammals. Int Rev Cytol 84:235–268
4. Baum M, Brinkley DM, Dossett JA, McPherson K, Patterson JS, Rubens RD, Smiddy FG, Stoll BA, Wilson A, Richards D and Ellis SH (1985): Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Lancet 1:836–840
5. Bern HA (1992a): Diethylstilbestrol (DES) syndrome: present status of animal and human studies. In: Hormonal Carcinogenesis. Li, J, Nandi S, Li SA, eds. Springer-Verlag, New York, pp 1–8